Yoon Heera, Kim Min Joon, Yoon Insoo, Li Dong Xing, Bae Hyunsu, Kim Sun Kwang
Department of Physiology, College of Korean Medicine, Kyung Hee University.
Biol Pharm Bull. 2015;38(5):710-4. doi: 10.1248/bpb.b14-00797. Epub 2015 Mar 5.
Oxaliplatin, a platinum-based chemotherapy drug, often induces acute neuropathic pain, especially cold allodynia, even after a single administration. Subcutaneous injection of diluted bee venom (BV) into acupoints has been used to treat various pain symptoms in traditional oriental medicine. Although we previously demonstrated the suppressive effect of BV injection on oxaliplatin-induced cold allodynia in rats, its neurochemical mechanism remained unclear. This study investigates whether and how the cholinergic system mediates the relieving effect of BV injection on cold allodynia in oxaliplatin-administered rats. The behavioral signs of cold allodynia induced by an oxaliplatin administration (6 mg/kg, intraperitoneally (i.p.)) were evaluated by a tail immersion test in cold water (4°C). BV (0.25 mg/kg, subcutaneously (s.c.)) injection into the Yaoyangguan acupoint, located between the spinous processes of the fourth and fifth lumbar vertebrae, significantly alleviated the cold allodynia. This relieving effect of BV injection on oxaliplatin-induced cold allodynia was blocked by a pretreatment with mecamylamine (a non-selective nicotinic receptor antagonist, 2 mg/kg, i.p.), but not by atropine (a non-selective muscarinic receptor antagonist, 1 mg/kg, i.p.). Further, dihydro-β-erythroidinehydrobromide (DHβE, an α4β2 nicotinic antagonist, 5 mg/kg, i.p.) prevented the anti-allodynic effect of BV, whereas methyllycaconitine (an α7 nicotinic antagonist, 6 mg/kg, i.p.) did not. Finally, intrathecal administration of DHβE (10 nM) blocked the BV-induced anti-allodynic effect. These results suggest that nicotinic acetylcholine receptors, especially spinal α4β2 receptors, but not muscarinic receptors, mediate the suppressive effect of BV injection on oxaliplatin-induced acute cold allodynia in rats.
奥沙利铂是一种铂类化疗药物,即使单次给药后也常诱发急性神经性疼痛,尤其是冷痛觉过敏。在传统东方医学中,将稀释的蜂毒(BV)皮下注射到穴位已被用于治疗各种疼痛症状。尽管我们之前证明了BV注射对奥沙利铂诱导的大鼠冷痛觉过敏有抑制作用,但其神经化学机制仍不清楚。本研究调查胆碱能系统是否以及如何介导BV注射对奥沙利铂给药大鼠冷痛觉过敏的缓解作用。通过冷水(4°C)尾浸试验评估奥沙利铂(6mg/kg,腹腔注射(i.p.))诱导的冷痛觉过敏的行为体征。将BV(0.25mg/kg,皮下注射(s.c.))注射到位于第四和第五腰椎棘突之间的腰阳关穴位,可显著减轻冷痛觉过敏。BV注射对奥沙利铂诱导的冷痛觉过敏的这种缓解作用被美加明(一种非选择性烟碱受体拮抗剂,2mg/kg,i.p.)预处理阻断,但未被阿托品(一种非选择性毒蕈碱受体拮抗剂,1mg/kg,i.p.)阻断。此外,氢溴酸二氢-β-刺桐啶(DHβE,一种α4β2烟碱拮抗剂,5mg/kg,i.p.)可阻止BV的抗痛觉过敏作用,而甲基lycaconitine(一种α7烟碱拮抗剂,6mg/kg,i.p.)则不能。最后,鞘内注射DHβE(10nM)可阻断BV诱导的抗痛觉过敏作用。这些结果表明,烟碱型乙酰胆碱受体,尤其是脊髓α4β2受体,而非毒蕈碱受体,介导了BV注射对奥沙利铂诱导的大鼠急性冷痛觉过敏的抑制作用。